A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Locally Advanced or Metastatic with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Brief description of study

If you have been diagnosed with Non-Small Cell Lung Cancer that has tested positive for the presence of EGFR or HER2 Exon 20 Insertion (lung cancer that involves a certain type of mutated or changed cells that may play a role in causing your cancer to grow and spread), you may qualify for this phase 2 study. The main goal of this research study is to determine the safety and how effective the investigational drug, Poziotnib, a targeted therapy designed to slow or stop certain types cancer cells by targeting specific changed or mutated molecules that help cancer cells grow or spread, is for the treatment for EGFR or HER2 Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer (NSCLC).

Clinical Study Identifier: s17-01530
ClinicalTrials.gov Identifier: NCT03318939

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.